Ohcanbohtosat - Jaume Mora

Aiddostahte ozu
  1. 1
    Risk–Benefit of Dexrazoxane for Preventing Anthracycline-Related Cardiotoxicity: Re-Evaluating the European Labeling

    Risk–Benefit of Dexrazoxane for Preventing Anthracycline-Related Cardiotoxicity: Re-Evaluating the European Labeling Dahkki Peter Reichardt, Marie‐Dominique Tabone, Jaume Mora, Bruce Morland, Robin L. Jones

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy

    Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy Dahkki Cristina Larrosa, Margarida Simão-Rafael, Noelia Salvador, Juan P. Muñoz, Cinzia Lavarino, Guillermo Chantada, Jaume Mora

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm

    Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm Dahkki Brigitte Royer‐Pokora, Maike Busch, Manfred Beier, Constanze Duhme, Carmen de Torres, Jaume Mora, Artur Brandt, Hans‐Dieter Royer

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    High TGFβ-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene

    High TGFβ-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene Dahkki Alejandra Bruna, Rachel S. Darken, Federico Rojo, Alberto Ocaña, Silvia Peñuelas, Alexandra Arias, Raquel Parı́s, Avelina Tortosa, Jaume Mora, José Baselga, Joan Seoane

    Almmustuhtton 2007
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery

    SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery Dahkki Carles Monterrubio, Guillem Pascual‐Pasto, Francisco Cano, Mònica Vilà-Ubach, Alejandro Manzanares, Paula Schaiquevich, José Antonio Tornero, Alejandro Sosnik, Jaume Mora, Ángel M. Carcaboso

    Almmustuhtton 2015
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients

    Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients Dahkki Alberto Cascón, Lucía Inglada‐Pérez, Iñaki Comino‐Méndez, Aguirre A. de Cubas, Rocío Letón, Jaume Mora, Mónica Marazuela, Juan Carlos Galofré, Miguel Quesada‐Charneco, Mercedes Robledo

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues

    Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues Dahkki Mònica Sánchez-Guixé, Ferran Muiños, Morena Pinheiro-Santin, Vı́ctor González-Huici, Carlos J. Rodríguez-Hernández, Alexandra Avgustinova, Cinzia Lavarino, Abel González-Pérez, Jaume Mora, Núria López-Bigas

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report

    Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—U... Dahkki Jaume Mora, Alicia Castañeda, Maite Gorostegui, Amalia Varo, Sara Pérez‐Jaume, Margarida Simão, Juan Pablo Muñoz Pérez, Moira Garraus, Cristina Larrosa, Noelia Salvador, Cinzia Lavarino, Lucas Krauel, Salvador Mañé

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Factors associated with the non detection of the sentinel node in breast cancer

    Factors associated with the non detection of the sentinel node in breast cancer Dahkki Guirao, Sara, Benítez Segura, Ana, Bajén, Maria Tereza, Brulles, Ynonet Ricart, Salvado, Jaume Mora, Vilardell, Ana Domenech, Rodriguez Gassen, Alba, Engronyat, Manel Roca, Puchal Añe, Rafael, Martin-Comin, Josep

    Almmustuhtton 2005
    Viečča ollesdeavstta
    Online
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

    A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers Dahkki Ryan S. Lee, Chip Stewart, Scott L. Carter, Lauren Ambrogio, Kristian Cibulskis, Carrie Sougnez, Michael S. Lawrence, Daniel Auclair, Jaume Mora, Todd R. Golub, Jaclyn A. Biegel, Gad Getz, Charles W.M. Roberts

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights

    DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights Dahkki Soledad Gómez, Giancarlo Castellano, Gemma Mayol, Mariona Suñol, Ana C. Queirós, Marina Bibikova, Kristopher L. Nazor, Jeanne F. Loring, Isadora Lemos, Eva Rodríguez, Carmen de Torres, Jaume Mora, José I. Martín‐Subero, Cinzia Lavarino

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

    The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial Dahkki Jaume Mora, Gcf Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Jörg Faber, Arthur Wingerter, Melissa K. Bear, Alba Rubio‐San‐Simón, Blanca Martínez de las Heras, Karen Tornøe, Maria Düring, Brian H. Kushner

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup

    Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup Dahkki F. Kommoss, Damian Stichel, Jaume Mora, Manel Esteller, David Jones, Stefan M. Pfister, Eva Brack, Marco Wachtel, Peter Bode, Hans‐Peter Sinn, Dietmar Schmidt, Thomas Mentzel, Friedrich Kommoss, Felix Sahm, Andreas von Deimling, Christian Koelsche

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma

    A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma Dahkki Idoia García, Gemma Mayol, José Ríos, Gema Doménech, Nai‐Kong V. Cheung, André Oberthuer, Matthias Fischer, John M. Maris, Garrett M. Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galván, Carmen de Torres, Jaume Mora, Cinzia Lavarino

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma

    Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma Dahkki Idoia García, Gemma Mayol, Eva Rodríguez, Mariona Suñol, Timothy R. Gershon, José Ríos, Nai‐Kong V. Cheung, Mark W. Kieran, Rani E. George, Antonio R. Pérez‐Atayde, Carla Casalà, Patricia Galván, Carmen de Torres, Jaume Mora, Cinzia Lavarino

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma

    EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma Dahkki Sílvia García-Monclús, Roser López‐Alemany, Olga Almacellas‐Rabaiget, David Herrero‐Martín, Juan Huertas-Martínez, Laura Lagares‐Tena, Piedad Alba‐Pavón, Lourdes Hontecillas‐Prieto, Jaume Mora, Enrique de Álava, Santiago Rello‐Varona, Paloma H. Giangrande, Òscar M. Tirado

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression

    Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression Dahkki Vito Alessandro Lasorsa, Daniela Formicola, Piero Pignataro, Flora Cimmino, Francesco Maria Calabrese, Jaume Mora, Maria Rosaria Esposito, Marcella Pantile, Carlo Zanon, Marilena De Mariano, Luca Longo, Michael D. Hogarty, Carmen de Torres, Gian Paolo Tonini, Achille Iolascon, Mario Capasso

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

    Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina Dahkki Rosé, Adriana, André, Nicolas, Rozados, Viviana R., Mainetti, Leandro E, Márquez, Mauricio Menacho, Rico, María José, Schaiquevich, Paula, Villarroel, Milena, Gregianin, Lauro, Graupera, Jaume Mora, García, Wendy Gómez, Epelman, Sidnei, Alasino, Carlos, Alonso, Daniel, Chantada, Guillermo, Scharovsky, O Graciela

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

    In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells Dahkki Marta Martínez-Lage, Raúl Torres, Pilar Puig-Serra, P. Moreno-Gaona, M. Cruz Martín, Francisco Moya, Oscar Quintana‐Bustamante, Susana García‐Silva, Ángel M. Carcaboso, Paolo Petazzi, Clara Bueno, Jaume Mora, Héctor Peinado, José C. Segovia, Pablo Menéndez, Sandra Rodríguez

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

    EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma Dahkki Amanda Balboni Iniguez, Björn Stolte, Emily Jue Wang, Amy Saur Conway, Gabriela Alexe, Neekesh V. Dharia, Nicholas Kwiatkowski, Tinghu Zhang, Brian J. Abraham, Jaume Mora, Peter Kalev, Alan L. Leggett, Dipanjan Chowdhury, Cyril H. Benes, Richard A. Young, Nathanael S. Gray, Kimberly Stegmaier

    Almmustuhtton 2018
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: